Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance

NF. Jensen, J. Stenvang, MK. Beck, B. Hanáková, KC. Belling, KN. Do, B. Viuff, SB. Nygård, R. Gupta, MH. Rasmussen, LS. Tarpgaard, TP. Hansen, E. Budinská, P. Pfeiffer, F. Bosman, S. Tejpar, A. Roth, M. Delorenzi, CL. Andersen, MU. Rømer, N....

. 2015 ; 9 (6) : 1169-85. [pub] 20150224

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010469

Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens with one of the two chemotherapeutic drugs, irinotecan or oxaliplatin. However, drug resistance frequently limits the clinical efficacy of these therapies. In order to gain new insights into mechanisms associated with chemoresistance, and departing from three distinct CRC cell models, we generated a panel of human colorectal cancer cell lines with acquired resistance to either oxaliplatin or irinotecan. We characterized the resistant cell line variants with regards to their drug resistance profile and transcriptome, and matched our results with datasets generated from relevant clinical material to derive putative resistance biomarkers. We found that the chemoresistant cell line variants had distinctive irinotecan- or oxaliplatin-specific resistance profiles, with non-reciprocal cross-resistance. Furthermore, we could identify several new, as well as some previously described, drug resistance-associated genes for each resistant cell line variant. Each chemoresistant cell line variant acquired a unique set of changes that may represent distinct functional subtypes of chemotherapy resistance. In addition, and given the potential implications for selection of subsequent treatment, we also performed an exploratory analysis, in relevant patient cohorts, of the predictive value of each of the specific genes identified in our cellular models.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010469
003      
CZ-PrNML
005      
20160415122000.0
007      
ta
008      
160408s2015 ne f 000 0|engg|
009      
AR
024    7_
$a 10.1016/j.molonc.2015.02.008 $2 doi
024    7_
$a 10.1016/j.molonc.2015.02.008 $2 doi
035    __
$a (PubMed)25759163
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Jensen, Niels F $u University of Copenhagen, Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Frederiksberg, Denmark.
245    10
$a Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance / $c NF. Jensen, J. Stenvang, MK. Beck, B. Hanáková, KC. Belling, KN. Do, B. Viuff, SB. Nygård, R. Gupta, MH. Rasmussen, LS. Tarpgaard, TP. Hansen, E. Budinská, P. Pfeiffer, F. Bosman, S. Tejpar, A. Roth, M. Delorenzi, CL. Andersen, MU. Rømer, N. Brünner, JM. Moreira,
520    9_
$a Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens with one of the two chemotherapeutic drugs, irinotecan or oxaliplatin. However, drug resistance frequently limits the clinical efficacy of these therapies. In order to gain new insights into mechanisms associated with chemoresistance, and departing from three distinct CRC cell models, we generated a panel of human colorectal cancer cell lines with acquired resistance to either oxaliplatin or irinotecan. We characterized the resistant cell line variants with regards to their drug resistance profile and transcriptome, and matched our results with datasets generated from relevant clinical material to derive putative resistance biomarkers. We found that the chemoresistant cell line variants had distinctive irinotecan- or oxaliplatin-specific resistance profiles, with non-reciprocal cross-resistance. Furthermore, we could identify several new, as well as some previously described, drug resistance-associated genes for each resistant cell line variant. Each chemoresistant cell line variant acquired a unique set of changes that may represent distinct functional subtypes of chemotherapy resistance. In addition, and given the potential implications for selection of subsequent treatment, we also performed an exploratory analysis, in relevant patient cohorts, of the predictive value of each of the specific genes identified in our cellular models.
650    _2
$a kamptothecin $x analogy a deriváty $x farmakologie $7 D002166
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a kolorektální nádory $x farmakoterapie $x genetika $x metabolismus $7 D015179
650    12
$a chemorezistence $7 D019008
650    _2
$a lidé $7 D006801
650    12
$a biologické modely $7 D008954
650    _2
$a organoplatinové sloučeniny $x farmakologie $7 D009944
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Stenvang, Jan $u University of Copenhagen, Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Frederiksberg, Denmark.
700    1_
$a Beck, Mette K $u Technical University of Denmark, Department for Systems Biology, Center for Biological Sequence Analysis, Lyngby, Denmark.
700    1_
$a Hanáková, Barbora $u Masaryk University, Faculty of Medicine, Institute of Biostatistics and Analyses, Brno, Czech Republic.
700    1_
$a Belling, Kirstine C $u Technical University of Denmark, Department for Systems Biology, Center for Biological Sequence Analysis, Lyngby, Denmark.
700    1_
$a Do, Khoa N $u Technical University of Denmark, Department for Systems Biology, Center for Biological Sequence Analysis, Lyngby, Denmark.
700    1_
$a Viuff, Birgitte $u University of Copenhagen, Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Frederiksberg, Denmark.
700    1_
$a Nygård, Sune B $u University of Copenhagen, Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Frederiksberg, Denmark.
700    1_
$a Gupta, Ramneek $u Technical University of Denmark, Department for Systems Biology, Center for Biological Sequence Analysis, Lyngby, Denmark.
700    1_
$a Rasmussen, Mads H $u Aarhus University Hospital, Department of Molecular Medicine, Aarhus, Denmark.
700    1_
$a Tarpgaard, Line S $u University of Southern Denmark, Institute of Clinical Research, Oncology Unit, Odense, Denmark.
700    1_
$a Hansen, Tine P $u University of Southern Denmark, Institute of Clinical Research, Pathology Unit, Odense, Denmark.
700    1_
$a Budinská, Eva $u Masaryk University, Faculty of Medicine, Institute of Biostatistics and Analyses, Brno, Czech Republic.
700    1_
$a Pfeiffer, Per $u University of Southern Denmark, Institute of Clinical Research, Oncology Unit, Odense, Denmark.
700    1_
$a Bosman, Fred $u University of Lausanne, University Institute of Pathology, Lausanne, Switzerland.
700    1_
$a Tejpar, Sabine $u University Hospital Gasthuisberg, Digestive Oncology Unit, Leuven, Belgium.
700    1_
$a Roth, Arnaud $u University Hospital of Geneva, Oncosurgery Unit, Geneva, Switzerland.
700    1_
$a Delorenzi, Mauro $u SIB Swiss Institute of Bioinformatics, Bioinformatics Core Facility, Lausanne, Switzerland; University of Lausanne, Ludwig Center for Cancer Research, Lausanne, Switzerland; University of Lausanne, Oncology Department, Lausanne, Switzerland.
700    1_
$a Andersen, Claus L $u Aarhus University Hospital, Department of Molecular Medicine, Aarhus, Denmark. $7 gn_A_00006060
700    1_
$a Rømer, Maria U $u University of Copenhagen, Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Frederiksberg, Denmark.
700    1_
$a Brünner, Nils $u University of Copenhagen, Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Frederiksberg, Denmark. Electronic address: nbr@sund.ku.dk.
700    1_
$a Moreira, José M A $u University of Copenhagen, Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, Frederiksberg, Denmark.
773    0_
$w MED00167281 $t Molecular oncology $x 1878-0261 $g Roč. 9, č. 6 (2015), s. 1169-85
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25759163 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160415122045 $b ABA008
999    __
$a ok $b bmc $g 1113898 $s 934837
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 9 $c 6 $d 1169-85 $e 20150224 $i 1878-0261 $m Molecular oncology $n Mol Oncol $x MED00167281
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace